Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

329 ARTÍCULOS , VIENDO DEL 136 AL 150

[Proposal of endogenous anticholinergic hypothesis in Alzheimer disease]

Hori K, Konishi K, Akita R, Tani M, Tomioka H, Kitajima Y, Yokoyama S, Azuma K, Ikuse D, Akashi N, Yuda H, Hachisu M.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2013 Jun;33(3):117-26.

Rivastigmine in the treatment of hypersexuality in Alzheimer disease

Canevelli M, Talarico G, Tosto G, Troili F, Lenzi GL, Bruno G.

Alzheimer Dis Assoc Disord. 2013 Jul-Sep;27(3):287-8. doi: 10.1097/WAD.0b013e31825c85ae.

Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer's disease

Zhong Y, Zheng X, Miao Y, Wan L, Yan H, Wang B.

Am J Med Sci. 2013 Mar;345(3):222-6. doi: 10.1097/MAJ.0b013e318255a8f9.

Potential immunotargets for Alzheimer's disease treatment strategies

Fernández PL, Britton GB, Rao KS.

J Alzheimers Dis. 2013;33(2):297-312. doi: 10.3233/JAD-2012-121222.

Immunotherapy against amyloid pathology in Alzheimer's disease

Galimberti D, Ghezzi L, Scarpini E.

J Neurol Sci. 2013 Oct 15;333(1-2):50-4. doi: 10.1016/j.jns.2012.12.013. Epub 2013 Jan 5.

Alzheimer's disease modeling: ups, downs, and perspectives for human induced pluripotent stem cells

Wojda U, Kuznicki J.

J Alzheimers Dis. 2013;34(3):563-88. doi: 10.3233/JAD-121984.

Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease

Burstein AH, Zhao Q, Ross J, Styren S, Landen JW, Ma WW, McCush F, Alvey C, Kupiec JW, Bednar MM.

Clin Neuropharmacol. 2013 Jan-Feb;36(1):8-13. doi: 10.1097/WNF.0b013e318279bcfa.

Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study

Landen JW, Zhao Q, Cohen S, Borrie M, Woodward M, Billing CB Jr, Bales K, Alvey C, McCush F, Yang J, Kupiec JW, Bednar MM.

Clin Neuropharmacol. 2013 Jan-Feb;36(1):14-23. doi: 10.1097/WNF.0b013e31827db49b.

Pharmacogenomics in Alzheimer's disease: a genome-wide association study of response to cholinesterase inhibitors

Martinelli-Boneschi F, Giacalone G, Magnani G, Biella G, Coppi E, Santangelo R, Brambilla P, Esposito F, Lupoli S, Clerici F, Benussi L, Ghidoni R, Galimberti D, Squitti R, Confaloni A, Bruno G, Pichler S, Mayhaus M, Riemenschneider M, Mariani C, Comi G, Scarpini E, Binetti G, Forloni G, Franceschi M, Albani D.

Neurobiol Aging. 2013 Jun;34(6):1711.e7-13. doi: 10.1016/j.neurobiolaging.2012.12.008. Epub 2013 Jan 29.

[Nitrergic cerebrovascular regulation as affected by donepezil]

Toda N.

Nihon Yakurigaku Zasshi. 2013 Mar;141(3):150-4. doi: 10.1254/fpj.141.150.

Potential repurposing of oncology drugs for the treatment of Alzheimer's disease

Araki W.

BMC Med. 2013 Mar 26;11:82. doi: 10.1186/1741-7015-11-82.

Motor effects of REAC in advanced Alzheimer's disease: results from a pilot trial

Olazarán J, González B, López-Álvarez J, Castagna A, Osa-Ruiz E, Herrero-Cano V, Agüera-Ortiz L, Rinaldi S, Martínez-Martín P.

J Alzheimers Dis. 2013;36(2):297-302. doi: 10.3233/JAD-130077.

Autophagy modulation for Alzheimer's disease therapy

Zhu XC, Yu JT, Jiang T, Tan L.

Mol Neurobiol. 2013 Dec;48(3):702-14. doi: 10.1007/s12035-013-8457-z. Epub 2013 Apr 27.

The neglected role of histamine in Alzheimer's disease

Naddafi F, Mirshafiey A.

Am J Alzheimers Dis Other Demen. 2013 Jun;28(4):327-36. doi: 10.1177/1533317513488925. Epub 2013 May 15.

Epigenetic mechanisms in Alzheimer's disease: implications for pathogenesis and therapy

Wang J, Yu JT, Tan MS, Jiang T, Tan L.

Ageing Res Rev. 2013 Sep;12(4):1024-41. doi: 10.1016/j.arr.2013.05.003. Epub 2013 May 17.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias